A lantibiotic solution against bacterial infections comprises an aqueous solvent, a water-soluble polymeric component, class I bacteriocins, and amphipathic molecules.

A lantibiotic solution against bacterial infections comprises an aqueous solvent, a water-soluble polymeric component, class I bacteriocins, and amphipathic molecules.

The present invention relates to an anticancer drug composition comprising, as an active ingredient, TLR5 agonist derived from flagellin. The TLR5 agonist derived from flagellin of the present invention can exhibit an anticancer or anticancer adjuvant effect alone or concurrently with an immune checkpoint blockade, and thus, can be developed as a cancer cell growth inhibitory active ingredient.

Disclosed are methods of administering one or more Bacillus strains to poultry. The Bacillus strains improve bacterial homeostasis in the gastrointestinal tract by inhibiting bacterial pathogens such as E. coli and Clostridium. Administering the Bacillus strains also improves performance such as weight gain and feed conversion. Useful combinations of Bacillus strains and methods of using one or more Bacillus strains are also provided.

Mycobacterium tuberculosis is the most common pathogenic agent responsible for tuberculosis (TB) infection. Over a period of time, the methods used for combating TB have become more challenging by the prevalence of multi-drug resistant and extensively drug resistant strains. The disclosure relates generally to method and system for combating infections due to Mycobacterium tuberculosis. The system provides strategies to combat pathogenic infections caused by multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of Mycobacterium tuberculosis. The strategy involves identifying potential target sites in a pathogen, which can be utilized to compromise its multiple virulence or essential functions at the same time. The present disclosure utilizes the fact that a conserved stretch of nucleotide repeat sequence occurring multiple times on a pathogen genome in genomic neighborhood of genes encoding virulence factors for pathogen survival can be targeted to disrupt the overall genetic machinery of the pathogen.

The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

Peptides related to certain portions of the arginine deiminase enzyme from the bacterium Streptococcus cristatus are provided that disrupt the formation and composition of biofilms containing the oral pathogen Porphyromonas gingivalis, and also modulate the virulence of P. gingivalis. Pharmaceutical compositions containing such peptides and method of using the same are disclosed.

Disclosed are molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), for use in treating or preventing of inflammatory diseases and/or conditions with an inflammatory aeitiology. The disclosed molecules may be of particular use in the treatment and/or prevention of diseases and/or conditions characterised by inflammation occurring as a consequence of a cascade of cytokines, inflammation that may occur in and around the tissues and/or structures of the lung and inflammation occurring as a result of an infection.

A therapeutic agent comprising Lon protease, or a variant or active fragment thereof, alpha-hemolysin, or a variant or active fragment thereof, CK1α1, or a variant or active fragment thereof, a c-MYB inhibitor and/or a CEBP-δ inhibitor, for use in therapy, with the proviso that the therapeutic agent does not comprise a bacteria or bacterial supernatant. Methods of production and use thereof.

The invention relates to a tetanus neurotoxin (TeNT) conjugate comprising a TeNT conjugated to at least one masking moiety (i) through an acid labile linkage or (ii) comprising a masking polypeptide. The invention also relates to a composition comprising the TeNT conjugate and therapeutic use of the TeNT conjugate or composition for treating hypotonia in a subject or enhancing muscle power and/or muscle tone and/or muscle healing and/or sporting performance.